Aurinia Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
Aurinia Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
1.3%
Buyback Yield
| Total Shareholder Yield | 1.3% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon
Nov 08Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Sep 06
Aurinia Pharmaceuticals Appears Undervalued
Jul 05We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
May 24Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report
May 05Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)
May 02Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
Apr 18Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
Mar 05Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report
Feb 19Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues
Feb 17Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon
Feb 15Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential
Jan 28We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
Jan 05Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price
Dec 18Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business
Sep 14Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement
Jun 11Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher
May 09We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn
May 01Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%
Nov 04Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus
Sep 19Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if AUPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AUPH's dividend payments have been increasing.
Dividend Yield vs Market
| Aurinia Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (AUPH) | n/a |
| Market Bottom 25% (US) | 1.3% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (AUPH) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate AUPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AUPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate AUPH's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AUPH has not reported any payouts.